Uncategorized
Glaukos reports optimistic outlook for growth of MIGS
Glaukos is advancing several new MIGS devices through the regulatory process as it continues to expand its reach on several continents, Thomas Burns, Glaukos president and CEO, told investors at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco.“Over the past 15 years, we’ve been dedicated to creating an entirely new market space within ophthalmology called MIGS, microincisional glaucoma surgery,” Burns said. “And in the process of doing that, we’ve developed a series of microstents which will be able to treat glaucoma from its most incipient stages of naïve (Read more...)